Vasella to leave Novartis in August


Veteran pharma executive Danial Vasella has unexpectedly announced his resignation as chair of the board of directors at Novartis after 17 years at the top of the company.

He will not seek re-election in February, paving the way for a new chair from 1 August. His successor will be Jörg Reinhardt, who is currently running the drug division at Bayer. Vice chair Ulrich Lehner will serve in the interim.

Vasella was chief executive from 1996 to 2010 and became chair in 1999. His resignation as chief executive in 2010 came after a string of attacks by militant animal rights activists aimed at him and his family. The incoming chair, Reinhardt, is a scientist by training, with a PhD in pharmaceutical sciences, who climbed the R&D ranks at Sandoz before the merger with Ciba-Geigy that created Novartis. He arrives at a challenging time for Novartis, which is struggling with the expiry of patents for many of its financially important drugs.


Related Content

Business roundup

26 February 2010 Business

news image

Industry news, March 2010

Business roundup

25 August 2009 Business

news image

Industry news, September 2009

Most Read

No-frills coats set a trend for designer viruses

26 August 2014 Research

news image

An artificial protein that self-assembles around and protects DNA could be ideal for gene therapy, nanomachines and synthetic...

First ionic liquid made from plant waste

27 August 2014 Research

news image

Closed loop recycling could see ionic liquids made from biofuel by-products used to make more biofuel

Most Commented

3D printing cuts fuel cell component costs

4 July 2014 Research

news image

Hardware hackers encouraged to exploit new manufacturing approach in open source schemes

Next Mars rover will make oxygen from CO2

4 August 2014 News and Analysis

news image

Mars 2020 will set Nasa’s space exploration on a self-sufficiency course